James Eadie, MD
Ophthalmology · Merrillville, INNPI 1205091097
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $8,600 of the $10,972 with a category attached, or 78.4%. Alimera Sciences, Inc. accounts for 87.3% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $5,894 and has fallen 94.9% since, to $299 in 2025. Among ophthalmology clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 32 payments — averaging $342.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alimera Sciences, Inc.$10K
- Regeneron Healthcare Solutions, Inc.$490
- Novartis$475
- AbbVie$296
- Regeneron$61
- ANI Pharmaceuticals, Inc.$39
- plus $27 from 2 others
What the payments were for
- Speaking & faculty fees$8,60078%
- Food & beverage$2,37222%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alimera Sciences, Inc. | 15 | $9,583 |
| Regeneron Healthcare Solutions, Inc. | 3 | $490 |
| Novartis | 4 | $475 |
| AbbVie | 5 | $296 |
| Regeneron | 1 | $61 |
| ANI Pharmaceuticals, Inc. | 2 | $39 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $14 |
| Baxter Healthcare | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,972 in reported general payments places this provider in the 90th percentile of 266 ophthalmology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 130 | $3,337 |
| Timolol Maleate | 33 | $667 |
| Difluprednate | 13 | $590 |
| Brimonidine Tartrate | 11 | $203 |
| Tobramycin | 44 | $200 |
| Ketorolac Tromethamine | 23 | $130 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Merrillville
- David GrossMerrillville$6K
- Jeffrey NelsonMerrillville$5K
- Shamik BafnaLafayette$505K
- Kevin WaltzIndianapolis$199K
- Janet HummerIndianapolis$96K
- Francis PriceIndianapolis$67K
- Omar DukarEvansville$43K
- Gerald RoperBatesville$34K
- Dwight SilveraEvansville$28K
- Michael OrrIndianapolis$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.